A Marketing plan on UL diclofenac sodium

This paper seeks to present a concrete marketing strategy for a new product of the Generics division of United Laboratories Inc. (ULI). ULI has a total of twelve divisions and according to its 1990 National Sales Performance, the top three income earner divisions are Westmont, contributing 16% to th...

Full description

Saved in:
Bibliographic Details
Main Authors: Baluyot, Gary, Macaranas, Cristobal, Tan, Shaofen
Format: text
Language:English
Published: Animo Repository 1991
Online Access:https://animorepository.dlsu.edu.ph/etd_bachelors/16784
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: De La Salle University
Language: English
id oai:animorepository.dlsu.edu.ph:etd_bachelors-17297
record_format eprints
spelling oai:animorepository.dlsu.edu.ph:etd_bachelors-172972021-12-13T01:49:32Z A Marketing plan on UL diclofenac sodium Baluyot, Gary Macaranas, Cristobal Tan, Shaofen This paper seeks to present a concrete marketing strategy for a new product of the Generics division of United Laboratories Inc. (ULI). ULI has a total of twelve divisions and according to its 1990 National Sales Performance, the top three income earner divisions are Westmont, contributing 16% to the company Therapharma with 15% and both Medichem and Biomedis with 11%. The Generics division however, was only able to contribute 1% to the sales of the whole company even though it has always been known for its high quality products and low pricing methods/strategies. The latest product of the UL Generics division (ULG) that will be added to its current product line is the UL Diclofenac Sodium. It will be launched in June of 1992 and it available in only one format, the 50 mg tablet. It is the belief of ULG that it will be able to bring in additional income for the company and can further expand if marketed extensively. This may only happen however, if the salesman of ULG will be able to sell 8,025 bottles of UL Diclofenac Sodium for the first year. This equals P 1,546,731.38 in sales for the division. Furthermore, ULG intends to capture .34% of the Anti-Rheumatics Non Steroid (ARNS) market segment of the pharmaceutical industry, as a conservative estimate. Its entry in the market next year marks its joining of other ULI branded counterparts in the market such as Dolfenal, Pyrazon, Arthrifen, Skelan and Ketofen. In order to make all these a reality, ULG is expected to take this marketing plan for UL Diclofenac Sodium seriously for this will serve as their guideline or reference point in implementing tactics and strategies against their competitors. The approach to be used in convincing and encouraging the identified target market of the product will rely on the marketing mix strategy of the product and since this is a new product, most of the attention will be focused on its positioning and low pricing strategy. Aside from this, this plan will also serve as the guide for ULG to effectively and efficiently penetrate the market at the least possible cost. 1991-01-01T08:00:00Z text https://animorepository.dlsu.edu.ph/etd_bachelors/16784 Bachelor's Theses English Animo Repository
institution De La Salle University
building De La Salle University Library
continent Asia
country Philippines
Philippines
content_provider De La Salle University Library
collection DLSU Institutional Repository
language English
description This paper seeks to present a concrete marketing strategy for a new product of the Generics division of United Laboratories Inc. (ULI). ULI has a total of twelve divisions and according to its 1990 National Sales Performance, the top three income earner divisions are Westmont, contributing 16% to the company Therapharma with 15% and both Medichem and Biomedis with 11%. The Generics division however, was only able to contribute 1% to the sales of the whole company even though it has always been known for its high quality products and low pricing methods/strategies. The latest product of the UL Generics division (ULG) that will be added to its current product line is the UL Diclofenac Sodium. It will be launched in June of 1992 and it available in only one format, the 50 mg tablet. It is the belief of ULG that it will be able to bring in additional income for the company and can further expand if marketed extensively. This may only happen however, if the salesman of ULG will be able to sell 8,025 bottles of UL Diclofenac Sodium for the first year. This equals P 1,546,731.38 in sales for the division. Furthermore, ULG intends to capture .34% of the Anti-Rheumatics Non Steroid (ARNS) market segment of the pharmaceutical industry, as a conservative estimate. Its entry in the market next year marks its joining of other ULI branded counterparts in the market such as Dolfenal, Pyrazon, Arthrifen, Skelan and Ketofen. In order to make all these a reality, ULG is expected to take this marketing plan for UL Diclofenac Sodium seriously for this will serve as their guideline or reference point in implementing tactics and strategies against their competitors. The approach to be used in convincing and encouraging the identified target market of the product will rely on the marketing mix strategy of the product and since this is a new product, most of the attention will be focused on its positioning and low pricing strategy. Aside from this, this plan will also serve as the guide for ULG to effectively and efficiently penetrate the market at the least possible cost.
format text
author Baluyot, Gary
Macaranas, Cristobal
Tan, Shaofen
spellingShingle Baluyot, Gary
Macaranas, Cristobal
Tan, Shaofen
A Marketing plan on UL diclofenac sodium
author_facet Baluyot, Gary
Macaranas, Cristobal
Tan, Shaofen
author_sort Baluyot, Gary
title A Marketing plan on UL diclofenac sodium
title_short A Marketing plan on UL diclofenac sodium
title_full A Marketing plan on UL diclofenac sodium
title_fullStr A Marketing plan on UL diclofenac sodium
title_full_unstemmed A Marketing plan on UL diclofenac sodium
title_sort marketing plan on ul diclofenac sodium
publisher Animo Repository
publishDate 1991
url https://animorepository.dlsu.edu.ph/etd_bachelors/16784
_version_ 1772835198097948672